Abstract Number: 1455 • 2012 ACR/ARHP Annual Meeting
Mitochondrial Dysfunction in the Liver of Lupus-Prone MRL/Lpr Mice Prior to Disease Onset
Background/Purpose: Liver dysfunction, characterized by serum elevation of liver enzymes, is detectable in 20% of patients with systemic lupus erythematosus (SLE.) Males had a higher…Abstract Number: 1416 • 2012 ACR/ARHP Annual Meeting
Tumor Necrosis Factor Alpha Is Associated with Mood Disorders in Patients with Systemic Lupus Erythematosus
Background/Purpose: Elevated serum levels of tumor necrosis factor alpha (TNF-α) have been reported in patients with major depressive disorder and in patients with depression in…Abstract Number: 1417 • 2012 ACR/ARHP Annual Meeting
Favorable Response to Belimumab At Three Months
Background/Purpose: Belimumab (Benlysta) is a monoclonal antibody that inhibits soluble B-Lymphocyte Stimulator and improves SLE disease activity. This study was initiated to evaluate the use…Abstract Number: 1418 • 2012 ACR/ARHP Annual Meeting
Directed Intuitive Assessment of Lupus (the DIAL system for real world clinics) Correlates Well with BILAG and SLEDAI
Background/Purpose: Disease activity measures used in SLE clinical studies, including the SLEDAI (SLE Disease Activity Index) and BILAG (British Isles Lupus Assessment Group) index are…Abstract Number: 1419 • 2012 ACR/ARHP Annual Meeting
Infections Increase Risk of Arterial and Venous Thromboses in Systemic Lupus Erythematosus Patients: 4925 Patient Years of Follow-up
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at increased risk of developing coronary heart disease as well as infections. Acute infections have been recognized…Abstract Number: 1420 • 2012 ACR/ARHP Annual Meeting
Ethnicity and B Cell Depletion Therapy in Systemic Lupus Erythematosus
Background/Purpose:The aim of this study was to determine if there is any relation between ethnicity and outcome in patients with SLE treated with B cell…Abstract Number: 1421 • 2012 ACR/ARHP Annual Meeting
Antimalarials Protect Systemic Lupus Erythematosus Patients From Damage Accrual During the First Five Years of the Disease
Background/Purpose: Studies in the last 20 years have demonstrated that antimalarials (AM) prevent flares, protect from damage accrual, reduce the risk of thrombosis and increase…Abstract Number: 1422 • 2012 ACR/ARHP Annual Meeting
Clinical Associations of Anti-Smith Antibodies in Profile: A Multiethnic Lupus Cohort
Background/Purpose: Anti-Smith (anti-Sm) antibodies are highly specific for systemic lupus erythematosus (SLE) and have an important value in the diagnosis of this disease. However, whether…Abstract Number: 1423 • 2012 ACR/ARHP Annual Meeting
Vascular Thrombosis and Pregnancy Morbidity in Patients with Systemic Lupus Erythematosus with Positive Antiphospholipid Profile and Thrombocytopenia
Background/Purpose: The trigger for a thrombotic in patients with antiphospholipid antibodies is unknown. Thrombocytopenia is among the most common clinical manifestations of the Antiphospholipid antibody…Abstract Number: 1424 • 2012 ACR/ARHP Annual Meeting
Prevalence and Clinical Significance of Severe Infection in Patients with Systemic Lupus Erythematosus: Preliminary Data From Relesser (Registry of lupus of the Spanish Society of Rheumatology)
Background/Purpose: Infection is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). Immunosuppression, comorbidities, and the disease itself makes patients with SLE…Abstract Number: 1425 • 2012 ACR/ARHP Annual Meeting
Circulating Free Protein S Levels May Be Linked to Cardiovascular Events and Venous Thrombosis in SLE
Background/Purpose: SLE patients are at risk for diverse organ systems involvement, which increases the challenges for diagnosis and predictions for the development of specific clinical…Abstract Number: 1426 • 2012 ACR/ARHP Annual Meeting
The Clinical Relevance of a “False Negative” Enzyme Linked Immunoassay: Which Antinuclear Antibody Screening Test Is Preferred by Rheumatologists in an Integrated Health System?
Background/Purpose: Historically, Immunofluorescence Assay (IFA) methodology has been the gold standard for ANA screening. Most clinical laboratories in recent years utilize the Enzyme Linked Immunoassay…Abstract Number: 1427 • 2012 ACR/ARHP Annual Meeting
Late Onset Systemic Lupus Erythematosus: Is It Actually A Milder Variant?
Background/Purpose: Classically, late onset Systemic Lupus Erythematosus (SLE) has been described as a milder variant of the disease. The objective of this study is to…Abstract Number: 1428 • 2012 ACR/ARHP Annual Meeting
Long-Term Outcomes of Children Born to Women with Systemic Lupus Erythematosus
Background/Purpose: SLE can cause considerable morbidity during pregnancy. Although several studies have evaluated foetal outcome in lupus pregnancy, very few have examined the long-term outcome…Abstract Number: 1429 • 2012 ACR/ARHP Annual Meeting
Women with Systemic Lupus Erythematosus (SLE) May Have Different Predictors of Risk for Progression of Aorta Calcium (AS) Than Women without SLE
Background/Purpose: Women with SLE have increased rates of subclinical atherosclerosis and cardiovascular (CV) events. We investigated which risk factors may be significant in the rate…